Industry News
Pharmaceutical Industry News
The FDA has denied ITM Isotopes…
The FDA has denied ITM Isotopes Technologies’ lead pipeline candidate for a rare group of tumors due to qualms over the drug’s manufacturing.
Abbott has enlisted telenovela…
Abbott has enlisted telenovela star Gabriela Spanic to push the message that getting screened for colon cancer doesn’t have to be dramatic.
Bristol Myers Squibb has laid out…
Bristol Myers Squibb has laid out plans for a $2.3 billion manufacturing facility in Houston, set for completion in 2030. The plant will cover 600,000 square feet and employ nearly 500 people.
Scholar Rock has dropped Novo…
Scholar Rock has dropped Novo Nordisk’s troubled Catalent facility as a contract manufacturer in its FDA refiling for apitegromab, a spinal muscular atrophy candidate, after a recent inspection of the plant was classified as “Official
Quanterix has hired medtech…
Quanterix has hired medtech veteran Jim Gute as chief commercial officer, bringing him over from Exact Sciences after an earlier 18-year career at GE Healthcare.
A Generation on Antidepressants Searches for the Exit
Many people feel that antidepressants block their true emotions, but they don’t have guidance about how to get off these drugs.
Injected weight loss drugs remain…
Injected weight loss drugs remain favored over newer oral treatments by a significant margin, with Eli Lilly’s Zepbound leading the pack, according to a survey of healthcare specialists by Spherix Global Insights.
Novo Nordisk has made Omnicom the…
Novo Nordisk has made Omnicom the agency of record for U.S. media buying, ending the drugmaker’s six-year partnership with WPP’s Wavemaker.
Fresenius Kabi voluntary recalled…
Fresenius Kabi voluntary recalled one lot of morphine sulfate injection due to a labelling mix-up with prefilled syringes of dilaudid that could trigger an overdose resulting in severe respiratory distress or death.
AbbVie retook the top spot from…
AbbVie retook the top spot from rival J&J and its immunology drug Tremfya in July’s top TV drug ad spending rankings.
A Promising Heart Drug Fails, Challenging a Long-Held Theory of Disease
The drug targeted inflammation, and its shocking failure has experts questioning whether inflammation really does cause heart disease.
The partnership marks Basuch +…
The partnership marks Basuch + Lomb's foray into the digital and AI healthcare space.
In a remarkable turnaround,…
In a remarkable turnaround, Replimune has reversed the fortune of its melanoma therapy, winning FDA approval after two prior rejections and agency leadership shakeups.
The company and the National…
The company and the National Psoriasis Foundation will celebrate the second annual Generalized Pustular Psoriasis Awareness day on August 13.
The new platform bolsters Inizio…
The new platform bolsters Inizio Engage's medical information capabilities with expanded global infrastructure and AI-enabled innovation.
Takeda’s first-in-class orexin…
Takeda's first-in-class orexin treatment won an FDA nod for narcolepsy. Daiichi Sankyo faced investor pushback after admitting to an accounting error. Astellas booked a new quarterly revenue record. And more.
Life sciences leaders are…
Life sciences leaders are rethinking patient support as AI, connected data and trust reshape engagement.
After coming up short with two…
After coming up short with two OX2R agonists, Takeda has scored with oveporexton, gaining FDA approval for the first-in-class drug as a treatment for adults with narcolepsy type 1. Orzeyful, as it will be known
In his first earnings call just…
In his first earnings call just days after becoming Sarepta Therapeutics' CEO, Michael Severino recognized that the rare disease drugmaker faces multiple upcoming milestones that will clarify its growth trajectory.
A New Plan for Closer U.S.-Israel Military Cooperation, and the First mRNA Flu Vaccine
Plus, what happens when you have an A.I. boss.